RecruitingPhase 2NCT05421325

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

Studying OBSOLETE: Other complex syndrome of primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Qu Biologics Inc.
Principal Investigator
Theodore Steiner, MD FRCPC
University of British Columbia
Intervention
QBKPN SSI(biological)
Enrollment
72 target
Eligibility
65 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

The National Research Council of Canada Industrial Research Assistance Program

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05421325 on ClinicalTrials.gov

Other trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

← Back to all trials